Dicle Şener Okur

Dr. Dicle Şener Okur

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Medecine Et Maladies Infectieuses
Verified
Journal Article
Closed access
YCY. Camcioglu
Y. Camcioglu
DODicle Şener Okur
Dicle Şener Okur
NAN. Aksaray
N. Aksaray
FDF. Darendeliler
F. Darendeliler
EHE. Hasanoglu
E. Hasanoglu

5 August 2022 in Medicine
Verified
Journal Article
Open access
DODicle Şener Okur
Dicle Şener Okur
There is insufficient evidence on SARS-CoV-2 induced neurological effects. Studies on CNS involvement during COVID-19 in children are limited. This study aims to identify and manage the neurological signs and symptoms in COVID-19-infected pediatric patients during follow up and plan future follow-ups. Children diagnosed COVID-19 and hospitalized in the pediatric pandemic services, between March 18, 2020, and June 18, 2021, were included in the study. Children with underlying neurological disease were excluded from the study. Patient data retrieved from hospital files and medical records. Children divided into 2 groups, 1 and 2, based on the presence or absence of neurological findings. A total of 243 children received follow-ups in the pandemic wards, 35 (14.4%) of these patients had neurological findings. Major neurological manifestations were headache (n:17, 7%), seizure (n:4, 1.6%), and anosmia/hyposmia (n:17, 7%). The number of boys (n:13, 37.1%) was smaller than the number of girls (n:22, 62.9%) in Group 1. Group 1 showed higher blood leukocyte, lymphocyte, thrombocyte, AST, LDH, d-dimer values. Anosmia/hyposmia occurred more often in girls, anosmia and headache occurred more often over 9 years of age. Pulmonary and hematologic involvement was more common in children with anosmia and headache. Our study is one of the few studies on neurological involvement in COVID-19 in children. To the best of our knowledge, there is limited data on these subjects in the literature.

16 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TKTuğba Gürsoy KOCA
Tuğba Gürsoy KOCA
DODicle Şener Okur
Dicle Şener Okur
AEAbdulkerim Elmas
Abdulkerim Elmas
HKHalil Kocamaz
Halil Kocamaz
MAMustafa Akcam
Mustafa Akcam
Background: Epstein–Barr virus (EBV) infection is common in childhood and frequently accompanied by liver enzyme abnormalities. Although hepatic involvement is generally self-limited, pediatric data on predictors of hepatitis and biochemical recovery dynamics remain limited. This study aimed to evaluate the frequency and severity of hepatic involvement in children with primary EBV infection and identify clinical and laboratory features associated with hepatitis. Methods: This retrospective cohort study included children aged 0–18 years with serologically confirmed primary EBV infection at a tertiary center between January 2015 and November 2024. Patients with cytomegalovirus co-infection, hepatotropic viral infections, chronic liver disease, hepatotoxic drug exposure, or incomplete records were excluded. Demographic, clinical, and laboratory data were collected. Hepatic involvement was defined as ALT elevation above age-adjusted upper limits. Group comparisons utilized appropriate parametric and non-parametric tests, and logistic regression assessed predictors of hepatitis. Results: A total of 294 patients were included (median age: 6.1 years), of whom 48.6% were male. Hepatitis occurred in 59.2% of cases. Children with hepatitis were older than those without (median 6.7 vs. 5.3 years, p < 0.001). Logistic regression demonstrated that increasing age independently predicted hepatitis (odds ratio per year increase: 1.010; 95%CI 1.005–1.015; p < 0.001). Median time to ALT normalization was 20 days, and no patient developed acute liver failure. Conclusions: Hepatic involvement is common in pediatric EBV infection and is more frequent in older children. Despite significant biochemical abnormalities, all patients recovered fully with supportive care. Recognizing age-related risk and typical recovery patterns may reduce unnecessary investigations and guide appropriate management in pediatric EBV hepatitis.

1 March 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
DODicle Şener Okur
Dicle Şener Okur
CYCaner Yuruyen
Caner Yuruyen
OGOzge Gungor
Ozge Gungor
ZAZerrin Aktas
Zerrin Aktas
ZEZayre Erturan
Zayre Erturan
KKKaya Koksalan
Kaya Koksalan
Objective: To identify epidemic and other transmissible Pseudomonas aeruginosa strains, genotypic analyses are required. The aim of this study was to assess the distribution of P. aeruginosa strains within the Turkish pediatric cystic fibrosis (CF) clinic population. Methods: Eighteen patients attending the pediatric CF clinic of Cerrahpasa Medical Faculty were investigated in the study. Throat swab and/or sputum samples were taken from each patient at 3-month intervals. The isolates of patients were analyzed by pulsed-field gel electrophoresis (PFGE). The intra- and interpatient genotypic heterogeneity of isolates was examined to determine the clonal isolates of P. aeruginosa within the cohort. Results: A total of 108 clinical isolates of P. aeruginosa were obtained from 18 patients between May 2013 and May 2014. The pulsotypes of the first patient’s isolates could not be obtained by PFGE. From the remaining 17 patients and 101 isolates, 55 distinct pulsotypes were detected. The number of pulsotypes observed in more than one patient (minor clonal strains, cluster strains) was 8 (14.5%), and one of them colonized three patients. However, none of them was detected in more than three patients. These pulsotypes were composed of 20 isolates. In addition, with the PFGE analysis of 81 isolates, we detected 47 (85.6%) pulsotypes, which belonged to only one patient. Over different periods of this study, only 2 (11.8%) patients were colonized with the same pulsotype. Conclusion: Our study indicates that there was considerable genomic diversity among the P. aeruginosa isolates in our clinic. The presence of shared pulsotypes supports cross-transmission between patients.

15 July 2026 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
SDSevliya Ocal Demir
Sevliya Ocal Demir
PEPınar Canizci Erdemli
Pınar Canizci Erdemli
ETEsra Cakmak Taskin
Esra Cakmak Taskin
AYAyşe Tekin Yılmaz
Ayşe Tekin Yılmaz
SSSemra Sen
Semra Sen
GAGülşen Akkoç
Gülşen Akkoç

23 December 2021 in Medicine
Verified
Journal Article
Open access
DODicle Şener Okur
Dicle Şener Okur
This study aims to explore the effects of new type of coronavirus disease (COVID-19) in children with neurological and/or neuromuscular diseases A retrospective study was conducted at State Hospital of Denizli. Pediatric patients diagnosed with COVID-19 who were hospitalized between March 18, 2020 and January 18, 2021 were included in the study. Children were divided into two groups: those with (group I) and without neurological and /or neuromuscular disorders (group II). Male cases were more than female cases in group I. The difference between group I and group II was significant in terms of seizure (47.3%; 1.7%), dyspnea (36.8%, 6.2%) and number of days with fever (2.6 ± 1.9; 1.58 ± 1.42) (P < .01, P < .01, P = .02). Hypoxemia (7, 11; 36.8%, 4.5%) and abnormal auscultation findings (8, 44; 42.1%, 18.1%) were more common in children in group I, hypertension was more common in group II (0, 8; 0%, 3.3%). Lung involvement of COVID-19 was found to be more severe in group I (P = .04). The frequency of hospitalization in the intensive care unit (P < .01) and application of noninvasive mechanical ventilation (NIMV) (P < .01); the number of days followed-up in the intensive care (P < .01) and in the hospital (P = .02) of the patients in group I were higher than those in group II. It is recognized that children with underlying neurological and/or neuromuscular diseases are severely affected by COVID-19.